New insider activity at Zenas BioPharma, Inc. ( (ZBIO) ) has taken place on February 12, 2025.
Director Ting Xiao has made a significant investment in Zenas BioPharma, Inc. by purchasing 10,000 shares of the company’s stock. This transaction is valued at $77,600, indicating confidence in the company’s future prospects.
Recent Updates on ZBIO stock
In recent developments, Zenas BioPharma has been the subject of several analyst actions. Wolfe Research initiated coverage on the company with an Outperform rating, citing the stock’s current trading near cash and the potential upside from the company’s catalysts outweighing the downside. This optimism comes despite the stock’s significant decline following a ‘November biotech debacle’ after its IPO in September 2024. Meanwhile, Morgan Stanley lowered its price target for Zenas BioPharma, reflecting caution in the market’s outlook, possibly due to prevailing market conditions or company-specific factors. These analyst actions highlight a mixed sentiment towards the company’s future prospects.
More about Zenas BioPharma, Inc.
YTD Price Performance: -15.98%
Average Trading Volume: 336,644
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $322.2M
Questions or Comments about the article? Write to editor@tipranks.com